

Technology Advisory Interests Register

Topic: Sparsentan for treating primary IgA nephropathy [ID6308]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Elizabeth Thurgar	TAC Committee Member	Direct- financial	Elizabeth is currently working with Pfizer in unrelated indication, NSCLC. She has also worked with Takeda, in last 12 months in unrelated indication, short bowel syndrome.	21/01/2025 09/04/2025	It was agreed that Elizabeth's declaration would not prevent them from participating in discussions on this appraisal
Michael Chambers	TAC Committee Member	Direct- financial	Mike has participated in an advisory panel for Pfizer (comparator company) in an unrelated disease area (prostate cancer). He has also provided consultancy advice to Sanofi on HTA methods (no Sanofi medicine discussed).	21/01/2025 09/04/2025	It was agreed that Michael's declaration would not prevent them from participating in discussions on this appraisal
Kate Ren	TAC Committee Member	Indirect - Professional Interests	Kate is a co-author of the EAG report for ID6308	21/01/2025	It was agreed that Kate's declaration would prevent them from participating in discussions on this appraisal
Satish Venkateshan	TAC Committee Member	Direct- financial	Regeneron is developing therapeutics for a broad range of diseases including in combination with cemdisiran. Satish works for Regeneron, pharmaceuticals/biotech	22/01/2025	It was agreed that Satish's declaration would prevent them from participating in

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			company. He also owns shares in the company and have stock options		discussions on this appraisal
Jonathan Barratt	Clinical Expert	Direct Financial Interests	Jonathan has provided independent consultancy advice to Traveře Therapeutics and CSL Vifor	28/03/2024	It was agreed that Jonathan's declaration would not prevent them from providing expert advice to the committee
		Indirect financial Interests	He has also received research funding from Traveře Therapeutics, administered through the University of Leicester.	28/03/2024	
		Indirect financial Interests	Consulting and Speaker Fees: Alexion, Alnylam, Argenx, Astellas, BioCryst, Calliditas, Chinook, Dimerix, Galapagos, Novartis, Omeros, Traveře Therapeutics, Vera Therapeutics, Visterra Grant Support: Alexion, Argenx, Calliditas, Chinook, Galapagos, GlaxoSmithKline, Novartis, Omeros, Traveře Therapeutics, Visterra	26/11/2024	

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Lisa Willcoks	Clinical Expert	Direct Financial Interests	<p>Lisa has participated in two paid Scientific Advisory Board for CSL Vifor.</p> <p>She has provided a one-hour educational webinar for CSL Vifor employees about IgA Nephropathy in January 2024.</p> <p>She has also participated in two Scientific Advisory Board for Trave Therapeutics.</p> <p>Finally, she gave a presentation at UKKW in 2021 paid for by Trave Therapeutics.</p>	<p>26/03/2024</p> <p>09/04/2025</p>	It was agreed that Lisa's declaration would not prevent them from providing expert advice to the committee
		Direct non-financial Interests	<p>Lisa is a Principal Investigator in the PROTECT trial, as well as the SPARTAN trial, both of which are assessing the role of Sparsentan in IgAN</p>	<p>26/03/2024</p> <p>09/04/2025</p>	
		Indirect Interests	<p>Lisa is a member of the NHS England Transform Clinical Reference Group (CRG) for Nephrology.</p>	<p>26/03/2024</p> <p>09/04/2025</p>	

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Benjamin Stokes	Clinical Expert	Indirect Interests	Benjamin is a Member of the Kidney Research UK Lay Advisory Group.	27/03/2024	It was agreed that Benjamins declaration would not prevent them from providing expert advice to the committee